PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma

Landon C. Brown; Jason Zhu; Matthew K. Labriola; Yuan Wu; Sachica Cheris; Xin Liu; Kathryn Perkinson; Zuowei Su; Shannon McCall; Jiaoti Huang; Wen Chi Foo; Rajan T. Gupta; Andrew J. Armstrong; Daniel J. George; Michael R. Harrison; Tian Zhang

doi:10.1016/j.clgc.2020.03.020

PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma

Landon C. Brown, Jason Zhu, Matthew K. Labriola, Yuan Wu, Sachica Cheris, Xin Liu, Kathryn Perkinson, Zuowei Su, Shannon McCall, Jiaoti Huang, Wen Chi Foo, Rajan T. Gupta, Andrew J. Armstrong, Daniel J. George, Michael R. Harrison, Tian Zhang

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Few studies have evaluated concordance between different commercially available programmed death-ligand 1 (PD-L1) assays. Tissue from 32 patients with metastatic renal cell carcinoma and 18 patients with metastatic urothelial carcinoma were assessed by 2 different PD-L1 assays each and found 91% and 94% concordance between assays, respectively. These results suggest strong concordance and similar performance characteristics across PD-L1 assays.

Original language	English (US)
Pages (from-to)	509-513
Number of pages	5
Journal	Clinical Genitourinary Cancer
Volume	18
Issue number	6
DOIs	https://doi.org/10.1016/j.clgc.2020.03.020
State	Published - Dec 2020
Externally published	Yes

Keywords

Biomarkers
Dako
Immunohistochemistry
Immunotherapy
Programmed death receptor-1

ASJC Scopus subject areas

Oncology
Urology

Access to Document

10.1016/j.clgc.2020.03.020

Cite this

Brown, L. C., Zhu, J., Labriola, M. K., Wu, Y., Cheris, S., Liu, X., Perkinson, K., Su, Z., McCall, S., Huang, J., Foo, W. C., Gupta, R. T., Armstrong, A. J., George, D. J., Harrison, M. R., & Zhang, T. (2020). PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma. Clinical Genitourinary Cancer, 18(6), 509-513. https://doi.org/10.1016/j.clgc.2020.03.020

Brown, LC, Zhu, J, Labriola, MK, Wu, Y, Cheris, S, Liu, X, Perkinson, K, Su, Z, McCall, S, Huang, J, Foo, WC, Gupta, RT, Armstrong, AJ, George, DJ, Harrison, MR & Zhang, T 2020, 'PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma', Clinical Genitourinary Cancer, vol. 18, no. 6, pp. 509-513. https://doi.org/10.1016/j.clgc.2020.03.020

@article{811c4493c0364f6a9d2582bd4aabc6d5,

title = "PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma",

abstract = "Few studies have evaluated concordance between different commercially available programmed death-ligand 1 (PD-L1) assays. Tissue from 32 patients with metastatic renal cell carcinoma and 18 patients with metastatic urothelial carcinoma were assessed by 2 different PD-L1 assays each and found 91% and 94% concordance between assays, respectively. These results suggest strong concordance and similar performance characteristics across PD-L1 assays.",

keywords = "Biomarkers, Dako, Immunohistochemistry, Immunotherapy, Programmed death receptor-1",

author = "Brown, {Landon C.} and Jason Zhu and Labriola, {Matthew K.} and Yuan Wu and Sachica Cheris and Xin Liu and Kathryn Perkinson and Zuowei Su and Shannon McCall and Jiaoti Huang and Foo, {Wen Chi} and Gupta, {Rajan T.} and Armstrong, {Andrew J.} and George, {Daniel J.} and Harrison, {Michael R.} and Tian Zhang",

note = "Funding Information: JZ reports consulting fees from NGM Bio and Bayer; and travel from Urotoday. JH reports consulting fees from Morehealth, OptraScan, Genetron, Gencode, York Biotechnology, Kingmed Diagnostics, and Gem Flower Healthcare; and is the founder of Sisu Pharma. RTG reports speakers bureau for Bayer Pharma AG; and consulting fees from Bayer Pharma AG, Invivo Corp, and Bard. AJA reports consulting fees from AstraZeneca, Merck, Dendreon, Janssen, Clovis, Bayer, and Medivation/Astellas; speaking fees from Bayer and Dendreon; and research funding to Duke from Janssen , Medivation /Astellas, Sanofi-aventis , Active Biotech , Bayer , Dendreon , Merck , AstraZenica , Genentech /Roche, BMS , Constellation , Novartis , and Pfizer . DJG reports Advisory board for Astellas, AstraZeneca, Capio Biosciences, and Modra Pharmaceuticals BV; consultant for Astellas, AstraZeneca, Bayer H/C Pharmaceuticals, BMS, Exelixis, Inc, Flatiron, Janssen Pharmaceuticals, Leidos Biomedical Research, Merck Sharp & Dohme, Michael J Hennessey Associates, Myovant Sciences, Inc, Physician Education Resource LLC, Pfizer, Sanofi, and Vizuri Health Sciences, LLC; honorarium from Bayer H/C Pharmaceuticals, EMD Serono, Exelixis, Inc, Ipsen, Michael J Hennessey Associates, Pfizer, Sanofi, UroGPO, and UroToday; research for Acerta Pharmaceuticals, Astellas, Bayer H/C Pharmaceuticals, BMS, Calithera, Exelixis, Inc, Janssen Pharmaceuticals, Novartis, Pfizer, and Sanofi; steering committee for Bayer H/C Pharmaceuticals, BMS, NCI, Nektar Therapeutics, and Pfizer; speaker for Bayer H/C Pharmaceuticals, Exelixis, Inc, and Sanofi; travel accomodations from Bayer H/C Pharmaceuticals, Exelixis, Inc, and Sanofi; independent data monitoring committee for Janssen; independent contractor for Axess Oncology; senior editor for American Association for Cancer Research; co-editor in chief for Millennium Medical Publishing, Clinical Advances in Hematology & Oncology. MRH reports consultancy for AstraZeneca, Bayer, Bristol-Myers Squibb, Exelixis, Genentech, Janssen, and Pfizer; speakers bureau for Exelixis and Genentech; research funding (to institution) from Acerta , Bristol-Myers Squibb , Clovis , Exelixis , Genentech , Merck , Pfizer , and Seattle Genetics . TZ reports research funding from AstraZeneca , Janssen , OmniSeq , PGDx , Pfizer , Merrimack , Abbvie /Stemcentrx, Novartis , Merck , Mirati , and Regeneron ; advisory/consultant role to Genentech Roche, Exelixis, Bayer, AstraZeneca, Pfizer, Sanofi-Aventis, Janssen, Foundation Medicine, Amgen, BMS, Merck, Pharmacyclics, and Seattle Genetics; speakers{\textquoteright} bureau for Genentech Roche, Exelixis, Sanofi-Aventis, and Genomic Health; stocks/employment from Capio Biosciences (spouse) and Archimmune Therapeutics (spouse). All other authors state that they have no conflicts of interest. Funding Information: JZ reports consulting fees from NGM Bio and Bayer; and travel from Urotoday. JH reports consulting fees from Morehealth, OptraScan, Genetron, Gencode, York Biotechnology, Kingmed Diagnostics, and Gem Flower Healthcare; and is the founder of Sisu Pharma. RTG reports speakers bureau for Bayer Pharma AG; and consulting fees from Bayer Pharma AG, Invivo Corp, and Bard. AJA reports consulting fees from AstraZeneca, Merck, Dendreon, Janssen, Clovis, Bayer, and Medivation/Astellas; speaking fees from Bayer and Dendreon; and research funding to Duke from Janssen, Medivation/Astellas, Sanofi-aventis, Active Biotech, Bayer, Dendreon, Merck, AstraZenica, Genentech/Roche, BMS, Constellation, Novartis, and Pfizer. DJG reports Advisory board for Astellas, AstraZeneca, Capio Biosciences, and Modra Pharmaceuticals BV; consultant for Astellas, AstraZeneca, Bayer H/C Pharmaceuticals, BMS, Exelixis, Inc, Flatiron, Janssen Pharmaceuticals, Leidos Biomedical Research, Merck Sharp & Dohme, Michael J Hennessey Associates, Myovant Sciences, Inc, Physician Education Resource LLC, Pfizer, Sanofi, and Vizuri Health Sciences, LLC; honorarium from Bayer H/C Pharmaceuticals, EMD Serono, Exelixis, Inc, Ipsen, Michael J Hennessey Associates, Pfizer, Sanofi, UroGPO, and UroToday; research for Acerta Pharmaceuticals, Astellas, Bayer H/C Pharmaceuticals, BMS, Calithera, Exelixis, Inc, Janssen Pharmaceuticals, Novartis, Pfizer, and Sanofi; steering committee for Bayer H/C Pharmaceuticals, BMS, NCI, Nektar Therapeutics, and Pfizer; speaker for Bayer H/C Pharmaceuticals, Exelixis, Inc, and Sanofi; travel accomodations from Bayer H/C Pharmaceuticals, Exelixis, Inc, and Sanofi; independent data monitoring committee for Janssen; independent contractor for Axess Oncology; senior editor for American Association for Cancer Research; co-editor in chief for Millennium Medical Publishing, Clinical Advances in Hematology & Oncology. MRH reports consultancy for AstraZeneca, Bayer, Bristol-Myers Squibb, Exelixis, Genentech, Janssen, and Pfizer; speakers bureau for Exelixis and Genentech; research funding (to institution) from Acerta, Bristol-Myers Squibb, Clovis, Exelixis, Genentech, Merck, Pfizer, and Seattle Genetics. TZ reports research funding from AstraZeneca, Janssen, OmniSeq, PGDx, Pfizer, Merrimack, Abbvie/Stemcentrx, Novartis, Merck, Mirati, and Regeneron; advisory/consultant role to Genentech Roche, Exelixis, Bayer, AstraZeneca, Pfizer, Sanofi-Aventis, Janssen, Foundation Medicine, Amgen, BMS, Merck, Pharmacyclics, and Seattle Genetics; speakers? bureau for Genentech Roche, Exelixis, Sanofi-Aventis, and Genomic Health; stocks/employment from Capio Biosciences (spouse) and Archimmune Therapeutics (spouse). All other authors state that they have no conflicts of interest. Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = dec,

doi = "10.1016/j.clgc.2020.03.020",

language = "English (US)",

volume = "18",

pages = "509--513",

journal = "Clinical Genitourinary Cancer",

issn = "1558-7673",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma

AU - Brown, Landon C.

AU - Zhu, Jason

AU - Labriola, Matthew K.

AU - Wu, Yuan

AU - Cheris, Sachica

AU - Liu, Xin

AU - Perkinson, Kathryn

AU - Su, Zuowei

AU - McCall, Shannon

AU - Huang, Jiaoti

AU - Foo, Wen Chi

AU - Gupta, Rajan T.

AU - Armstrong, Andrew J.

AU - George, Daniel J.

AU - Harrison, Michael R.

AU - Zhang, Tian

N1 - Funding Information: JZ reports consulting fees from NGM Bio and Bayer; and travel from Urotoday. JH reports consulting fees from Morehealth, OptraScan, Genetron, Gencode, York Biotechnology, Kingmed Diagnostics, and Gem Flower Healthcare; and is the founder of Sisu Pharma. RTG reports speakers bureau for Bayer Pharma AG; and consulting fees from Bayer Pharma AG, Invivo Corp, and Bard. AJA reports consulting fees from AstraZeneca, Merck, Dendreon, Janssen, Clovis, Bayer, and Medivation/Astellas; speaking fees from Bayer and Dendreon; and research funding to Duke from Janssen , Medivation /Astellas, Sanofi-aventis , Active Biotech , Bayer , Dendreon , Merck , AstraZenica , Genentech /Roche, BMS , Constellation , Novartis , and Pfizer . DJG reports Advisory board for Astellas, AstraZeneca, Capio Biosciences, and Modra Pharmaceuticals BV; consultant for Astellas, AstraZeneca, Bayer H/C Pharmaceuticals, BMS, Exelixis, Inc, Flatiron, Janssen Pharmaceuticals, Leidos Biomedical Research, Merck Sharp & Dohme, Michael J Hennessey Associates, Myovant Sciences, Inc, Physician Education Resource LLC, Pfizer, Sanofi, and Vizuri Health Sciences, LLC; honorarium from Bayer H/C Pharmaceuticals, EMD Serono, Exelixis, Inc, Ipsen, Michael J Hennessey Associates, Pfizer, Sanofi, UroGPO, and UroToday; research for Acerta Pharmaceuticals, Astellas, Bayer H/C Pharmaceuticals, BMS, Calithera, Exelixis, Inc, Janssen Pharmaceuticals, Novartis, Pfizer, and Sanofi; steering committee for Bayer H/C Pharmaceuticals, BMS, NCI, Nektar Therapeutics, and Pfizer; speaker for Bayer H/C Pharmaceuticals, Exelixis, Inc, and Sanofi; travel accomodations from Bayer H/C Pharmaceuticals, Exelixis, Inc, and Sanofi; independent data monitoring committee for Janssen; independent contractor for Axess Oncology; senior editor for American Association for Cancer Research; co-editor in chief for Millennium Medical Publishing, Clinical Advances in Hematology & Oncology. MRH reports consultancy for AstraZeneca, Bayer, Bristol-Myers Squibb, Exelixis, Genentech, Janssen, and Pfizer; speakers bureau for Exelixis and Genentech; research funding (to institution) from Acerta , Bristol-Myers Squibb , Clovis , Exelixis , Genentech , Merck , Pfizer , and Seattle Genetics . TZ reports research funding from AstraZeneca , Janssen , OmniSeq , PGDx , Pfizer , Merrimack , Abbvie /Stemcentrx, Novartis , Merck , Mirati , and Regeneron ; advisory/consultant role to Genentech Roche, Exelixis, Bayer, AstraZeneca, Pfizer, Sanofi-Aventis, Janssen, Foundation Medicine, Amgen, BMS, Merck, Pharmacyclics, and Seattle Genetics; speakers’ bureau for Genentech Roche, Exelixis, Sanofi-Aventis, and Genomic Health; stocks/employment from Capio Biosciences (spouse) and Archimmune Therapeutics (spouse). All other authors state that they have no conflicts of interest. Funding Information: JZ reports consulting fees from NGM Bio and Bayer; and travel from Urotoday. JH reports consulting fees from Morehealth, OptraScan, Genetron, Gencode, York Biotechnology, Kingmed Diagnostics, and Gem Flower Healthcare; and is the founder of Sisu Pharma. RTG reports speakers bureau for Bayer Pharma AG; and consulting fees from Bayer Pharma AG, Invivo Corp, and Bard. AJA reports consulting fees from AstraZeneca, Merck, Dendreon, Janssen, Clovis, Bayer, and Medivation/Astellas; speaking fees from Bayer and Dendreon; and research funding to Duke from Janssen, Medivation/Astellas, Sanofi-aventis, Active Biotech, Bayer, Dendreon, Merck, AstraZenica, Genentech/Roche, BMS, Constellation, Novartis, and Pfizer. DJG reports Advisory board for Astellas, AstraZeneca, Capio Biosciences, and Modra Pharmaceuticals BV; consultant for Astellas, AstraZeneca, Bayer H/C Pharmaceuticals, BMS, Exelixis, Inc, Flatiron, Janssen Pharmaceuticals, Leidos Biomedical Research, Merck Sharp & Dohme, Michael J Hennessey Associates, Myovant Sciences, Inc, Physician Education Resource LLC, Pfizer, Sanofi, and Vizuri Health Sciences, LLC; honorarium from Bayer H/C Pharmaceuticals, EMD Serono, Exelixis, Inc, Ipsen, Michael J Hennessey Associates, Pfizer, Sanofi, UroGPO, and UroToday; research for Acerta Pharmaceuticals, Astellas, Bayer H/C Pharmaceuticals, BMS, Calithera, Exelixis, Inc, Janssen Pharmaceuticals, Novartis, Pfizer, and Sanofi; steering committee for Bayer H/C Pharmaceuticals, BMS, NCI, Nektar Therapeutics, and Pfizer; speaker for Bayer H/C Pharmaceuticals, Exelixis, Inc, and Sanofi; travel accomodations from Bayer H/C Pharmaceuticals, Exelixis, Inc, and Sanofi; independent data monitoring committee for Janssen; independent contractor for Axess Oncology; senior editor for American Association for Cancer Research; co-editor in chief for Millennium Medical Publishing, Clinical Advances in Hematology & Oncology. MRH reports consultancy for AstraZeneca, Bayer, Bristol-Myers Squibb, Exelixis, Genentech, Janssen, and Pfizer; speakers bureau for Exelixis and Genentech; research funding (to institution) from Acerta, Bristol-Myers Squibb, Clovis, Exelixis, Genentech, Merck, Pfizer, and Seattle Genetics. TZ reports research funding from AstraZeneca, Janssen, OmniSeq, PGDx, Pfizer, Merrimack, Abbvie/Stemcentrx, Novartis, Merck, Mirati, and Regeneron; advisory/consultant role to Genentech Roche, Exelixis, Bayer, AstraZeneca, Pfizer, Sanofi-Aventis, Janssen, Foundation Medicine, Amgen, BMS, Merck, Pharmacyclics, and Seattle Genetics; speakers? bureau for Genentech Roche, Exelixis, Sanofi-Aventis, and Genomic Health; stocks/employment from Capio Biosciences (spouse) and Archimmune Therapeutics (spouse). All other authors state that they have no conflicts of interest. Publisher Copyright: © 2020 Elsevier Inc.

PY - 2020/12

Y1 - 2020/12

N2 - Few studies have evaluated concordance between different commercially available programmed death-ligand 1 (PD-L1) assays. Tissue from 32 patients with metastatic renal cell carcinoma and 18 patients with metastatic urothelial carcinoma were assessed by 2 different PD-L1 assays each and found 91% and 94% concordance between assays, respectively. These results suggest strong concordance and similar performance characteristics across PD-L1 assays.

AB - Few studies have evaluated concordance between different commercially available programmed death-ligand 1 (PD-L1) assays. Tissue from 32 patients with metastatic renal cell carcinoma and 18 patients with metastatic urothelial carcinoma were assessed by 2 different PD-L1 assays each and found 91% and 94% concordance between assays, respectively. These results suggest strong concordance and similar performance characteristics across PD-L1 assays.

KW - Biomarkers

KW - Dako

KW - Immunohistochemistry

KW - Immunotherapy

KW - Programmed death receptor-1

UR - http://www.scopus.com/inward/record.url?scp=85085610498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085610498&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2020.03.020

DO - 10.1016/j.clgc.2020.03.020

M3 - Article

C2 - 32482566

AN - SCOPUS:85085610498

SN - 1558-7673

VL - 18

SP - 509

EP - 513

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

IS - 6

ER -

PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this